The process of drug discovery remains a slow and challenging journey, even with advancements in artificial intelligence. Peter Ray, a medicinal chemist at Recursion, has dedicated his life to developing cancer drugs, driven by a promise he made to his mother after witnessing her battle with the disease. Despite the potential of AI to accelerate drug development, the path from identifying a target protein to creating a successful drug involves numerous trials and errors. Chemists and biologists must meticulously design and test molecules, yet more than 90% of potential drugs fail during trials. Keith Mikule of Insilico Medicine shares the rarity of success in this field, with only a few reaching the market, such as niraparib for ovarian cancer. This highlights the ongoing challenges and the incremental progress in using AI for drug discovery.<\/p>\n","protected":false},"excerpt":{"rendered":"
The process of drug discovery remains a slow and challenging journey, even with advancements in artificial intelligence. Peter Ray, a medicinal chemist at Recursion, has dedicated his life to developing…<\/p>\n","protected":false},"author":1,"featured_media":951,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1434],"tags":[1189,2631,1643,7226,413],"class_list":["post-9519","post","type-post","status-publish","format-standard","has-post-thumbnail","category-global","tag-ai-in-healthcare","tag-biotechnology","tag-cancer-research","tag-drug-development","tag-global-startup-news"],"acf":[],"yoast_head":"\n